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Runt-related transcription factor 1; SCC, squamous cell carcinoma
Research. 
on August 16, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 14, 2017; DOI: 10.1158/0008-5472.CAN-17-0418 
 3 
Abstract 
Nuclear focal adhesion kinase (FAK) is a potentially important regulator of gene 
expression in cancer, impacting both cellular function and the composition of the 
surrounding tumor microenvironment. Here we report in a murine model of skin 
squamous cell carcinoma (SCC) that nuclear FAK regulates Runx1-dependent 
transcription of insulin-like growth factor binding protein 3 (IGFBP3), and that this 
regulates SCC cell cycle progression and tumor growth in vivo. Furthermore, we 
identified a novel molecular complex between FAK and Runx1 in the nucleus of SCC 
cells and showed that FAK interacted with a number of Runx1 regulatory proteins, 
including Sin3a and other epigenetic modifiers known to alter Runx1 transcriptional 
function through post-translational modification. These findings provide important 
new insights into the role of FAK as a scaffolding protein in molecular complexes that 
regulate gene transcription.
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Introduction 
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that controls 
diverse cellular functions including cell adhesion, migration, invasion, polarity, 
proliferation, and survival (1,2). FAK is therefore involved in a number of processes 
that can impact on the malignant phenotype. Deletion of fak in mouse models of 
cancer has shown a requirement for FAK in tumor formation and progression (3-9). 
Over-expression of FAK has also been reported in a number of human epithelial 
tumors (10-12), and it has therefore emerged as a potential target for cancer therapy, 
with a number of FAK kinase inhibitors currently being developed (13). 
FAK was identified as a protein highly phosphorylated in response to integrin 
activation and primarily located at cell–extracellular matrix adhesion sites termed 
focal adhesions (1). Recent reports have also identified that FAK contains nuclear 
localization signals within the F2 lobe of the four-point-one, ezrin, radixin, moesin 
(FERM) domain (14) and a nuclear export signal within the kinase domain (15). 
Therefore, FAK can translocate to the nucleus, where its function remains poorly 
characterized. Within the nucleus, the FAK FERM domain can bind to the 
transcription factors p53 and GATA4, resulting in their turnover and inactivation, 
thereby controlling cell survival and inflammatory signals (14,16). Recently, we 
reported that nuclear FAK was tethered to chromatin and regulated the expression of 
chemokines and cytokines, including Ccl5 and TGF2, that contribute to 
establishment of an immuno-suppressive tumor environment through driving elevated 
intra-tumoral regulatory T-cell numbers (17). Therefore, nuclear FAK protein 
complexes can act to regulate transcriptional programs important in controlling 
cellular responses and the composition of the tumor immune environment.  
Runt-related transcription factor 1 (Runx1; also known as AML1) is one of a 
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family of three transcription factors (Runx1 - 3) that can either activate or repress 
transcription depending on the target gene, cell type, and associated co-factors 
(18,19). It has been shown to have a critical role in hematopoiesis and hematopoietic 
function (20), and is essential for mammalian development (21). In the context of 
cancer, Runx1 is best known for its role in acute myeloid leukemia (AML) where it is 
frequently found mutated (18). In recent years it has also become clear that Runx1 
plays an important role in solid epithelial malignancies. For example, Runx1 
deficiency impairs mouse skin tumorigenesis (22), while in contrast it acts as a tumor 
suppressor in the ApcMin mouse model of colorectal carcinogenesis (23). Therefore, it 
has an important but context dependent function in cancer. Here, we identify a novel 
molecular complex between FAK and Runx1 in the nucleus of skin squamous cell 
carcinoma (SCC) cells. We show that nuclear FAK and Runx1 cooperate to regulate 
expression of IGFBP3, and that IGFBP3 regulates cell cycle progression and tumor 
growth in vivo. Using proteomics and network biology approaches, we identify that 
nuclear FAK interacts with a number of Runx1 regulatory proteins that can alter 
Runx1 transcriptional function through post-translational modification. Further, we 
identify a novel interaction between nuclear FAK and Sin3a, a core component of the 
Sin3a/HDAC co-repressor complex, and show that Runx1/Sin3a interaction is 
enhanced in SCC FAK-wt cells. This study provides new insights into the potential 
mechanisms through which nuclear FAK regulates transcription factor function to 
control cell behavior.  
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Materials and Methods 
Materials. All antibodies used are listed in Supplementary Materials and Methods. 
All siRNA was purchased from Dharmacon and shRNA from Open Biosystems.  
Cell lines. Cell lines used in this study were generated, authenticated and 
characterized as previously described (17,24). Cells were pathogen tested in 
September 2016 using the ImpactIII test (Idex Bioresearch) and were negative for all 
pathogens. Cell lines are routinely tested for mycoplasma every 2-3 months in-house 
and have never been found to be mycoplasma positive. Cell lines are cultured for no 
more than 3 months following freeze thawing. Runx1 or scrambled siRNA was 
transiently transfected into SCC cells using HiPerFect (Qiagen). Cells were left for 3 
days and then immunoblotting or (q)RT-PCR analysis was carried out. Cell lines 
stably expressing FUCCI, Runx1, or empty-vector shRNA were generated by 
lentiviral infection and selected in 2 µg/ml puromycin. 
Generation of nuclear-targeting FAK mutants. Point mutations were introduced 
into wild-type FAK in three different combinations, (1) R177A and R178A, (2) 
K190A and K191A, (3) K216A and K218A, using site-directed mutagenesis as 
previously described (17). Primer sequences are listed in Supplementary Materials 
and Methods. 
Quantitative RT-PCR. RNA extracts were obtained using an RNeasy kit (Qiagen), 
following manufacturer’s instructions. cDNA was made using a first-strand cDNA 
synthesis kit (Invitrogen). (q)RT-PCR was performed as previously described (17). 
Analysis was performed using Rotor-Gene software, and expression relative to B2M 
was calculated using Excel (Microsoft). Standard PCR was performed using the above 
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conditions but substituting SensiFAST for a 2× PCR master mix. Primers used are 
listed in Supplementary Materials and Methods.  
Nuclear fractionation and total cell lysates. Cells were collected by scraping and 
low-speed centrifugation (1,000g at 4 °C for 5 min), followed by two washes with ice-
cold PBS. Cell pellets were resuspended in buffer A (10 mM KCl, 10 mM HEPES, 
pH 7.9, 0.5 mM DTT, 1.5 mM MgCl2) and incubated on ice for 15 min. Cells were 
lysed using a 25G needle and nuclei isolated by centrifugation at 12,000g at 4 °C for 
30 sec. The nuclear pellet was washed twice in buffer A and incubated in buffer C 
(25% (v/v) glycerol, 0.2 mM EDTA, pH 8.0, 0.42 M NaCl, 0.5 mM PMSF, 20 mM 
HEPES, pH 7.9, 0.5 mM DTT, 1.5 mM MgCl2) at 4 °C for 1 h. Clarification of the 
nuclear extracts was by high-speed centrifugation (16,000g at 4 °C for 5 min). 
Alternatively, cells were washed with PBS and lysed in RIPA lysis buffer (50 mM 
Tris–HCl, pH 7.4, 150 mM sodium chloride, 0.1% SDS and 1% sodium deoxycholate) 
with inhibitors (Complete Protease Inhibitor Cocktail and PhosSTOP; Roche). 
Clarification was by high-speed centrifugation (16,000g at 4 °C for 15 min). 
Immunoblotting and immunoprecipitation. Cell lysates or cell fractions (10–20 μg 
protein, as measured by Micro BCA Protein Assay kit (Pierce)) were supplemented 
with SDS sample buffer (Tris, pH 6.8, 20% glycerol, 5% SDS, β-mercaptoethanol, 
and bromophenol blue), separated by SDS–PAGE, transferred to nitrocellulose and 
immunoblotted with specific antibodies at 1:1000 dilution. For immunoprecipitation 
experiments, 0.25–1 mg of cell lysate or cell fraction was immunoprecipitated with 
either 5 μl of mouse Runx1 antibody, 10 μl of agarose-conjugated mouse FAK 
antibody, 10 μl of agarose-conjugated Myc-tag, or 10 μl of agarose-conjugated 
control IgG, and immune complexes collected. Beads were washed three times with 
lysis buffer, once with 0.6 M lithium chloride, and then added to SDS sample buffer. 
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2D-Gel Electrophoresis. Two-dimensional SDS–polyacrylamide gel 
electrophoresis was performed using the ZOOM IPGRunner System (ThermoFisher 
Scientific) according to the manufacturers protocol. Gels were transferred to 
nitrocellulose membranes, blocked (5 % BSA in TBST) and probed with anti-RUNX1 
antibody. 
Protein capture arrays. 2 × 106 SCC cells were plated onto a 90-mm tissue culture 
dish and allowed to adhere overnight. Growth medium was removed and replaced 
with 5 ml of normal growth medium. Cells were cultured for a further 24 hours before 
conditioned medium was removed and centrifuged at 1000 rpm for 5 minutes. 
Supernatant was collected and used for analysis. To control for cell number, the 90-
mm dish containing SCC cells was lysed in RIPA buffer and protein quantified using 
a BCA protein assay as described above. This was used to normalize loading of 
conditioned media onto the protein capture arrays. Secreted protein analysis was 
performed using mouse angiogenesis protein capture arrays (R & D Systems) 
according to the manufacturer’s protocol. The only modification was the use of a 
streptavidin DyLight-800 antibody for detection (1:10,000 dilution, Rockland 
Biochemicals). Image acquisition and analysis was performed using a Licor Imager. 
Mean spot intensities were calculated from duplicate arrayed spots per cell line. Data 
were median centered and subjected to unsupervised agglomerative hierarchical 
clustering on the basis of Pearson correlation computed with a complete-linkage 
matrix using Cluster 3.0 (C Clustering Library, version 1.50) (25). Clustering results 
were visualized using Java TreeView (version 1.1.6) (26). 
Blood vessel immunostaining. Subcutaneous tumors were surgically excised, 
placed in an aluminum foil boat, submerged in OCT compound, and snap frozen 
using a dry ice and methanol bath. OCT-embedded samples were stored long-term at 
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−80C. For analysis, sections were cut at −20C onto siliconized microscope slides. 
For staining, sections were removed from the −20C freezer, and 50 l of fixative  
was applied directly onto the tissue. Sections were incubated for 8 minutes at 4C and 
then the fixative removed and the slides allowed to equilibrate to room temperature 
for approximately 10–20 minutes. Sections were then rehydrated in PBS for 10 
minutes. The area of tissue was surrounded with a hydrophobic barrier pen and 
blocked using 1% horse serum in PBS for 30 minutes at room temperature. Tissue 
was then incubated with anti-CD31 antibody (BD Biosciences, 1:100 dilution in 
incubation buffer (1% bovine serum albumin, 1% normal donkey serum, 0.3% Triton 
X-100, 0.01% sodium azide in PBS)) overnight at 4C. Slides were washed three 
times for 15 minutes with PBS, and then incubated with anti-rat Alexa Fluor 594-
conjugated secondary antibody (Molecular Probes, ThermoFisher Scientific) diluted 
at 1:200 in incubation buffer for 1 hour at room temperature. Slides were washed 
three times for 15 minutes in PBS and then counter-stained with DAPI for 5 minutes. 
Slides were washed once for 15 minutes in PBS and mounted in VectaShield anti-fade 
mounting media (Vectorlabs). Images were acquired using an Olympus FV1000 
confocal microscope.  
Transcription factor network analysis. Transcription factors were extracted from 
the DECODE database (Qiagen), selecting the most relevant transcription factors 
predicted by text mining to bind between 20 kb upstream and 10 kb downstream of 
the human transcription starting site. The transcription factor Runx1 was used to seed 
a network of 1000 related proteins using the GeneMANIA plugin (version 3.4.1; 
human interactions) in Cytoscape (version 3.3.0) (27), onto which proteins 
specifically isolated in nuclear FAK protein complexes (17) were mapped. The 
resulting interactome was extracted, and proteins with physical or predicted direct or 
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indirect interactions with Runx1 were analyzed and topological network parameters 
computed using the NetworkAnalyzer plugin (version 2.7). Networks were clustered 
using the yFiles Organic algorithm implemented in Cytoscape. Pathway enrichment 
analysis was performed using the Database for Annotation, Visualization and 
Integrated Discovery (version 6.8) (28). Pathway terms with Benjamini–Hochberg-
corrected P-value < 0.01 were considered significantly overrepresented. 
Subcutaneous tumor growth. 2.5 × 105 cells were injected subcutaneously into each 
flank of immune-compromised CD-1 nude mice, and tumor growth measured twice 
weekly using calipers. Measurements were taken from three mice (each bearing two 
tumors) for each cell line, and the volume of the tumor (v) was calculated in Excel 
using the formula v = 4/3.π.r3. Data were graphed and statistics calculated using Prism 
(GraphPad). 
In vivo cell cycle analyses. Optical window chambers were implanted onto CD-1 
nude mice as described previously (29). All animal work was carried out in 
compliance with UK Home Office guidelines. 1 × 106 FUCCI-expressing SCC cells 
were injected into the dermis and at the time of window implantation. 24 hours later, 
mice were anaesthetized using an isoflurane–oxygen mix and three-dimensional 
image stacks acquired using an Olympus FV1000 confocal microscope. Image 
analysis was performed using the spot detection tool in Imaris (Bitplane). The number 
of green, red, and double-positive nuclei were counted and calculated as a percentage 
of the total number of cells within the image stack.  
Longitudinal in vivo imaging of tumor angiogenesis. Optical window chambers were 
implanted onto CD-1 nude mice as described above. Prior to sealing the window with 
a coverslip, a tagRFP-expressing tumor fragment (~1 mm in diameter) was placed 
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into the window. To obtain tumor fragments, a donor animal was injected with 2.5 × 
105 tagRFP-expressing SCC cells 10 days prior to optical window implantation. 
Tumors were removed, cut into small pieces using a scalpel, and fluorescence 
checked using an Olympus OV110 whole-animal imaging system. For longitudinal 
imaging of tumor angiogenesis, mice bearing optical windows were anaesthetized 
using an isoflurane–oxygen mix. Images were acquired 2, 4, 7, and 9 days post-
implantation using an Olympus OV110 whole-animal imaging system set to acquire 
both GFP and RFP signals using the zoom lens set to 1.6× magnification. For image 
analysis and identification of blood vessels, autofluorescence images acquired using 
the GFP channel were inverted in ImageJ. The tubness plugin was used to detect 
blood vessel structures and apply an image mask over these structures. The accuracy 
of this was checked manually. The vascular density was determined by calculating the 
percentage of the field of view covered by the vascular image mask. Data were 
graphed and statistics calculated using Prism. 
 
Results 
FAK is required for cell cycle progression and angiogenesis in SCC tumors 
We have previously shown using a murine model of skin SCC that depletion of FAK 
expression can result in immune-mediated tumor regression in syngeneic mice, and a 
growth delay in immune-deficient mice (17,24). We therefore sought to further 
dissect the complex role of FAK in regulating SCC tumor growth. We measured 
tumor growth in CD-1 nude mice following injection of 0.25 x 106 FAK-deficient 
cells (SCC FAK-/-) and FAK-deficient cells that re-expressed wild type FAK (SCC 
FAK-wt) at close to endogenous levels. As previously reported, SCC FAK-/- tumors 
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exhibited a growth delay when compared to SCC FAK-wt tumors (24) (Fig. 1a) that 
was associated with an increased tumor doubling time (Fig. 1b). FAK is a protein that 
plays a pleiotropic role in regulating cancer development and progression, and we 
hypothesized that a number of its reported functions, including regulation of 
proliferation/cell cycle and tumor angiogenesis (1,2,30), may contribute to the 
observed tumor growth delay in SCC FAK-/- tumors when established on an immune 
deficient host background. Thus, we set out to use intravital imaging to analyze, in 
real-time, the cell cycle distribution and kinetics of tumor neo-angiogenesis in SCC 
FAK-wt and SCC FAK-/- tumors when grown on CD-1 nude mice. 
To measure cell cycle distribution in real-time, SCC FAK-wt and SCC FAK-/- 
cells expressing the fluorescent ubiquitination-based cell-cycle indicator (FUCCI) 
reporter (31) were implanted via intra-dermal injection under dorsal-skinfold imaging 
windows. The FUCCI probe is based on the differential proteolysis of geminin and 
cdt1 at specific phases of the cell cycle, allowing differential profiling of cells at G1 
(red), G1/S (yellow), and S/G2/M (green) phases. Images of FUCCI-expressing SCC 
FAK-wt and SCC FAK-/- tumors revealed an increased number of red fluorescent 
cells in SCC FAK-/- tumors (Fig. 1c). Analysis of the proportion of red, yellow, and 
green nuclei from three-dimensional image stacks acquired 24 hours after tumor cell 
implantation identified a specific delay in the G1 phase of the cell cycle in SCC FAK-
/- tumor cells (Fig. 1d).  
FAK, expressed in cancer cells, has been reported to influence tumor angiogenesis 
through regulating the expression of vascular endothelial growth factor (VEGF) (30). 
To ascertain whether defective tumor neo-angiogenesis may also be occurring in SCC 
FAK-/- tumors, we performed longitudinal imaging of tagRFP-labeled SCC FAK-wt 
and SCC FAK-/- tumors under dorsal-skinfold windows. Using acquisition 
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parameters similar to those required to image green fluorescent protein (GFP), we 
acquired images of tissue autofluorescence, in which blood vessels appear as dark 
non-fluorescent structures that can be readily visualized. Longitudinal imaging of 
neo-angiogenesis revealed a significant decrease in vascular density in SCC FAK-/- 
tumors when compared to SCC FAK-wt tumors (Figs. 1e and 1f). Thus, SCC FAK-/- 
tumors exhibit defective cell cycle progression and neo-angiogenesis that may 
contribute to defective tumor growth in CD-1 nude mice. 
FAK negatively regulates transcription of IGFBP3 
We and others have previously identified that FAK can regulate the expression of 
secreted proteins that have the potential to act in both an autocrine and paracrine 
manner to influence cancer cell behavior and the surrounding tumor 
microenvironment (17,32,33). To investigate whether FAK-dependent regulation of 
secreted factors in SCC cancer cells could influence cell cycle progression and tumor 
angiogenesis, we screened for secreted factors implicated in both processes using 
protein capture arrays. Analysis of 53 secreted factors revealed both positive and 
negative regulation as a consequence of FAK expression (Fig. 2a and 
Supplementary Fig. 1). Applying a four-fold cutoff for differential regulation, we 
identified IGFBP3 as the most highly upregulated protein in SCC FAK-/- conditioned 
medium, while PDGF-AA, PDGF-AB/BB, FGF-1, and MMP-3 were the most highly 
upregulated proteins identified in SCC FAK-wt conditioned medium. Using these 
findings, we focused on IGFBP3, a protein belonging to the family of insulin-like 
growth factor binding proteins (IGFBPs), as this factor has previously been reported 
to negatively regulate both cell cycle progression (34,35) and angiogenesis (36-38). 
Western blot analysis of conditioned media confirmed an upregulation of IGFBP3 in 
SCC FAK-/- conditioned samples (Fig. 2b), and q(RT)-PCR identified similar 
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regulation of Igfbp3 gene transcript levels (Fig. 2c). Thus, we conclude that FAK 
negatively regulates the transcription of Igfbp3, leading to reduced levels of 
extracellular secreted IGFBP3 protein. 
 IGFBP3 is a member of a family of six proteins, IGFBP1–6 (39). However, 
only antibody capture pairs specific for IGFBP1, 2, and 3 were present on the protein 
capture arrays used. Therefore, we sought to determine whether FAK regulated the 
expression of other IGFBP family members. Employing sequence-specific primers 
designed for each of the six IGFBPs, we used PCR to screen for expression in cDNA 
libraries prepared from SCC FAK-wt and SCC FAK-/- cells (Fig. 2d). Aside from 
Igfbp3, only expression of Igfbp4 and Igfbp6 could be detected following 20 cycles of 
PCR. All primer sets were confirmed to produce single products of the correct size 
using cDNA prepared from mouse liver (Supplementary Fig. 2). (q)RT-PCR 
analysis of Igfbp4 expression revealed no differential regulation (Fig. 2e), whereas 
Igfbp6 expression was observed to exhibit a small but significant decrease in SCC 
FAK-/- cells when compared to SCC FAK-wt (Fig. 2f). Therefore, IGFBP3 was the 
only IGFBP family member to be negatively regulated in response to FAK 
expression. 
FAK kinase activity is not required for regulation of IGFBP3 
There has been considerable interest in targeting FAK function as a cancer therapy, 
and a number of small molecule FAK kinase inhibitors are now in early-phase clinical 
development (13). To determine the role of FAKs kinase activity in regulation of 
IGFBP3, we tested IGFBP3 protein expression using an SCC FAK-/- cell line in 
which a FAK kinase-deficient mutant (FAK-kd) had been re-expressed to levels 
comparable with SCC FAK-wt cells. Anti-IGFBP3 western blotting from conditioned 
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media revealed that IGFBP3 expression in SCC FAK-kd cells was similar to that 
observed in SCC FAK-wt cells (Fig. 2g), implying that FAK-dependent regulation of 
IGFBP3 expression was independent of FAK kinase activity. 
IGFBP3 regulates cell cycle progression but not angiogenesis to influence tumor 
growth 
To determine whether increased IGFBP3 expression in SCC FAK-/- cells contributed 
to the defective growth of SCC FAK-/- tumors, we generated SCC FAK-/- cells with 
a stable knockdown of IGFBP3 using shRNA (Fig. 3a). Analysis of subcutaneous 
tumor growth showed that knock-down of IGFBP3 in SCC FAK-/- cells partially 
restored tumor growth in vivo (Fig. 3b), resulting in an average tumor volume of 
approximately double the size when compared to SCC FAK-/- tumors on day 12. 
Using intravital imaging together with the FUCCI cell cycle reporter, we identified 
that the G1 arrest observed in SCC FAK-/- cells in vivo was overcome following 
IGFBP3 depletion (Figs. 3c and 3d). However, the defect in blood vessel formation 
was still evident in the SCC FAK-/- shRNA-IGFBP3 tumors as measured by the 
presence of CD31+ vessels (Figs. 3e and 3f). Therefore, IGFBP3 likely contributes to 
regulation of SCC tumor growth through controlling cell cycle progression, but not 
angiogenesis. Furthermore, depletion of IGFBP3 in SCC FAK-/- cells was not 
sufficient to fully restore tumor growth, implying that regulation of angiogenesis is 
likely also important.  
FAK nuclear localization is required for regulation of IGFBP3 transcription 
We have recently reported in SCC cells that nuclear FAK can bind to transcription 
factors and transcriptional regulators with the potential to influence gene expression 
(17). To investigate the requirement for FAK nuclear localization in regulation of 
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Igfbp3, we made a series of FAK nuclear targeting mutants according to previously 
reported findings that identified putative nuclear localization sequences within the F2 
lobe of the FERM domain (40), and expressed these in SCC FAK-/- cells. A total of 
three nuclear targeting mutants were constructed as follows: (1) by replacing arginine 
residues at positions 177 and 178 with alanines (FAK-177/178), (2) by replacing 
lysine residues at positions 190 and 191 with alanines (FAK-190/191), and (3) by 
replacing lysine residues at positions 216 and 218 with alanines (FAK-216/218). We 
have previously reported a fourth mutant deficient in nuclear targeting, in which all 
six of these amino acid residues have been replaced with alanines (17). Biochemical 
fractionation followed by western blotting was used to assess nuclear/cytoplasmic 
distribution of the resulting mutants when re-expressed in SCC FAK-/- cells, 
revealing that all four mutant FAK proteins were deficient in their ability to localize 
to the nucleus (Fig. 4a). Given that all of the double mutants appeared as defective in 
nuclear translocation as the mutant harboring all six mutations, we chose to move 
forward with these for further analysis. (q)RT-PCR analysis of Igfbp3 expression in 
cell lines expressing these mutant FAK proteins revealed significantly increased 
levels of Igfbp3 transcript in all three cell lines (Fig. 4b), implying a crucial role for 
FAK nuclear targeting in the transcriptional regulation of Igfbp3. The inability of 
these mutants to completely restore Igfbp3 transcript levels to that of SCC FAK-/- 
cells is likely the consequence of low levels of residual nuclear FAK (Fig. 4a). 
Runx1 is required for FAK-dependent transcriptional regulation of IGFBP3 
To better define the link between nuclear FAK and regulation of Igfbp3 transcription, 
we next sought to identify transcription factors with predicted binding sites in the 
promoter of the Igfbp3 gene. Using the DECODE database (Qiagen), we generated a 
list of transcription factors predicted by text mining to bind between 20 kb upstream 
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and 10 kb downstream of the human transcription start site (Fig. 4c). Of these 
transcription factors, three – Sp1, Runx1, and components of the transcription factor 
IID complex (TFIID) – were detected by mass spectrometry in a nuclear FAK 
interactome in SCC cells (Fig. 4c, dark grey bars) (17). We noted that the 
transcription factor Runx1, which has been reported to regulate Igfbp3 gene 
expression (41), had the most Igfbp3 promoter binding sites predicted by text mining 
(Fig. 4c). Moreover, Runx1 was not among the top transcription factors predicted to 
bind to the gene promoters of the other secreted proteins in the cluster highly 
upregulated in SCC FAK-/- conditioned medium (Supplementary Fig. 1, top cluster, 
and Supplementary Fig. 3), suggesting that these other angiogenesis-related proteins 
may be transcriptionally regulated by a distinct mechanism to Igfbp3.  
Using shRNA-mediated stable knockdown of Runx1 expression, we next 
determined whether Runx1 was required for IGFBP3 expression in SCC FAK-wt and 
SCC FAK-/- cells. Biochemical fractionation followed by western blotting confirmed 
a substantial knockdown of Runx1 expression in both SCC FAK-wt shRNA-Runx1 
and SCC FAK-/- shRNA-Runx1 cells (Fig. 4d) when compared to controls. Analysis 
of Igfbp3 expression in these cell lines using (q)RT-PCR showed a loss of Igfbp3 gene 
expression in SCC FAK-/- shRNA-Runx1 cells, reverting expression levels down to 
those observed in SCC FAK-wt vector-only control cells (Fig. 4e). Thus, Runx1 is 
required for increased Igfbp3 transcription following FAK loss in SCC cells. Using an 
independent method of expression knockdown, similar results were observed 
following depletion of Runx1 using siRNAs (Supplementary Fig. 4).  
FAK is in a complex with Runx1 in the nucleus 
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Analysis of Runx1 expression in SCC FAK-wt and FAK-/- cells revealed that Runx1 
is exclusively expressed in the nucleus, and that its expression level is not regulated 
by FAK (Fig. 4d). Hence, regulation of Runx1 expression / degradation is unlikely 
the mechanism through which FAK controls Runx1 transcriptional activity in SCC 
cells. Runx1 can act as either a transcriptional activator or repressor, and the 
composition of the proteins interacting with Runx1 at a given gene can modulate this 
function (18). Using a mass spectrometry dataset of the nuclear FAK interactome in 
SCC cells (17) we identified a potential FAK / Runx1 interaction. Co-
immunoprecipitation of Runx1 and FAK in SCC FAK-wt but not in SCC FAK-/- cells 
confirmed a novel association between FAK and Runx1 (Figs. 5a and 5b). Thus, 
nuclear FAK exists in complex with Runx1 under steady-state conditions in SCC 
cancer cells. 
A key mechanism of Runx1 regulation is post-translational modification. 
Runx1 interacts with a number of proteins including kinases, histone 
acetyltransferases, arginine methyltransferases, and histone deacetylases that can post-
translationally modify Runx1, switching it between transcriptional activation and 
repression (18,19). To further explore how FAK influences Runx1 function, we 
examined the Runx1 interaction landscape in the context of FAK. To do this, we 
constructed a Runx1 protein interaction network in silico, onto which we mapped the 
experimentally derived nuclear FAK interactome. This integrated interaction network 
identified a subnetwork of Runx1 regulators and associated proteins that interact with 
FAK in the nuclei of SCC cells (Fig. 5c and Supplementary Fig. 5). Interestingly, a 
number of these proteins, including DNA (cytosine-5)-methyltransferase 1 (Dnmt1), 
Sin3a, Histone deacetylases 1, 2, and 3 (HDAC1, 2, and 3), and Nuclear receptor 
corepressor 1 and 2 (NCoR1 and 2), are linked to repression of Runx1 transcriptional 
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activity (18,19). Therefore, nuclear FAK interacts with proteins that can regulate the 
post-translational modification and transcriptional function of Runx1. KEGG analysis 
also identified an enrichment for proteins with roles in the cell cycle (Fig. 5d and 
Supplementary Table 1), consistent with a complex that may play a wider role in the 
regulation of cell cycle progression.   
To determine whether FAK regulated Runx1 tyrosine phosphorylation, we 
used immunoprecipitation of tyrosine phosphorylated proteins from SCC FAK-wt and 
FAK-/- cell lysates, followed by western blotting and detection with an anti-Runx1 
antibody. No regulation of Runx1 tyrosine phosphorylation was observed (Fig. 5e). 
To assess Runx1 post-translational modification on a wider scale we performed 2D 
gel electrophoresis using nuclear extracts prepared from SCC FAK-wt and FAK-/- 
cells, and probed these gels with an anti-Runx1 antibody. This identified a number of 
potential differences in both the migration and intensity of spots detected (Fig. 5f, red 
arrows highlight changes), consistent with an altered state of post-translational 
modification.  
We next investigated whether FAK regulated proteins associated with the 
post-translational modification of Runx1. Based on data presented in Fig. 5c, we 
focused on Sin3a, a transcriptional co-repressor known to interact with a number of 
HDACs (42) and suppress Runx1 transcriptional activity (43). Western blotting 
using an anti-Sin3a antibody identified reduced Sin3a levels in the nucleus of SCC 
FAK-/- cells when compared to SCC FAK-wt cells (Fig. 5g). Co-
immunoprecipitation from SCC FAK-wt and FAK-/- nuclear extracts confirmed a 
novel association between Sin3a and FAK in SCC FAK-wt cells (Fig. 5h). Thus, 
FAK is in complex with and regulates the nuclear levels of a Sin3a. 
Immunoprecipitation of Runx1 from SCC FAK-wt and FAK-/- nuclear extracts 
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followed by western blotting and detection with an anti-Sin3a antibody confirmed an 
association between Runx1 and Sin3a in SCC FAK-wt cells (Fig. 5i). No interaction 
was observed in SCC FAK-/- cells. Therefore, we propose that one potential 
mechanism through which FAK may influence the post-translational modification and 
transcriptional activity of Runx1, is through regulating the expression and subsequent 
recruitment of Sin3a to Runx1 transcriptional complexes.   
 
Discussion 
Numerous studies have demonstrated the importance of FAK in regulating tumor cell 
behavior, which has largely been linked to its role in integrating signals from adhesion 
sites and growth factor receptors at the cell periphery to control cell adhesion, 
migration and survival (1,2). In addition, it is now becoming clear that FAK can also 
play a role within the nucleus to control gene expression (14,17,44). However, the 
mechanisms underpinning this function remain to be fully characterized. A number of 
nuclear FAK binding proteins have now been identified including the transcription 
factors p53 and GATA4 (14,16). Recently, we have shown that nuclear FAK is 
associated with chromatin and interacts with transcription factors, including the TBP-
associated factor TAF9, and transcriptional regulators reported or predicted to 
regulate expression of the chemokine Ccl5. In doing so, it controls the transcription of 
chemokines that regulate the composition of the immuno-suppressive tumor 
environment required to evade the CD8+ T-cell anti-tumor immune response (17). 
Here, we identify a novel interaction between nuclear FAK and the transcription 
factor Runx1. We show that nuclear FAK controls the Runx1 dependent expression of 
IGFBP3, which in turn regulates cell cycle progression and SCC tumor growth in 
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vivo. Further, we identify that FAK interacts with and regulates the nuclear levels of 
Sin3a, and that FAK is required for recruitment of Sin3a into complex with Runx1. 
Therefore, nuclear FAK can regulate transcription factor activity, potentially via 
recruitment of proteins to transcriptional complexes that can alter transcription factor 
post-translational modification, thereby controlling expression of specific genes that 
can play an important role in regulating both tumor cell behavior, and how tumor cells 
influence the composition of the tumor immune environment.  
Runx1 is a transcription factor with an important role in both normal development 
and disease (20,21). De-regulation of Runx1 function contributes to the development 
of hematological malignances, and in solid epithelial cancers, it has been identified as 
both a tumor promoter and a tumor suppressor (19). Runx1 can either activate or 
repress transcription depending on the composition of the protein complexes with 
which it is associated at a given gene (18), and this likely contributes to the 
complexity of its role in regulating tumorigenesis. It is known to interact with an array 
of proteins including kinases, histone acetyltransferases, arginine methyltransferases, 
histone deacetylases, and ubiquitin ligases, all of which can post-translationally 
modify Runx1 to regulate its transcriptional function (18,19). Using mass 
spectrometry, we show that FAK interacts with a number of these proteins including 
Dnmt1, Sin3a, HDACs 1, 2, and 3, and NCoR1 and 2, all of which are known to 
repress Runx1 function (18,19). Co-immunoprecipitation experiments confirmed a 
novel interaction between Sin3a and FAK, and further identified a requirement for 
FAK to promote interaction of Runx1 with Sin3a.  Supporting this as a potential 
mechanism of FAK-dependent Runx1 regulation, 2D gel analysis of nuclear extracts 
from SCC FAK-wt and FAK-/- cells using an anti-Runx1 antibody identified several 
protein species that show differential migration, consistent with altered post-
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translational modification.  Notably, post-translational modification is an important 
mechanism in the general regulation of transcription factor function (45). Thus, we 
conclude that this may represent a previously unknown mode of FAK-dependent 
regulation of gene expression.  
FAK is known to regulate a number of cellular processes important for the 
malignant phenotype (1,2). Here, we identify a new role for nuclear FAK in 
regulation of SCC cell cycle progression in vivo via controlling Runx1-dependent 
expression of IGFBP3. IGFBP3 has been linked to cell cycle arrest in tumor cells 
previously where a G1 arrest was accompanied by reduction in a number of cyclins, 
including cyclin D1, CDKs, and increased p21 expression (34,35). IGFBP3 has also 
been linked to regulation of angiogenesis (36-38). However, knockdown of IGFBP3 
in the SCC cells had no effect on tumor angiogenesis. Analysis of secreted proteins 
present in SCC conditioned media identified a number of changes including multiple 
factors that can influence tumor angiogenesis, implying that other factors may be 
more important in the regulation of angiogenesis in our SCC model. Interestingly, 
analysis of the predicted transcription factor binding sites in the promoters of other 
angiogenesis-related genes regulated by FAK identified that their mechanism of 
regulation is likely distinct to that of IGFBP3, highlighting the potential mechanistic 
diversity underpinning FAK-dependent transcriptional regulation. 
The data presented here sheds new light on the possible mechanisms underpinning 
nuclear FAK-dependent regulation of gene expression, highlighting the importance of 
FAK as a scaffold for protein interactions in the nucleus. Future work should focus on 
FAK associated transcription factors to define how their interactome may change in 
the absence of FAK, or its kinase activity, and what the biological and potential 
clinical relevance of these changes may be. 
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Figure Legends 
Figure 1 | FAK regulates SCC tumor growth, cell cycle and angiogenesis in vivo. 
(a) Growth of SCC FAK-wt and SCC FAK-/- tumor xenografts in CD-1 nude mice. n 
= 5 - 6 tumors per group. (b) SCC FAK-wt and SCC FAK-/- tumor doubling time. 
Unpaired T-test, ****p < 0.0001. (c) Intra-vital imaging of FUCCI expressing SCC 
FAK-wt and SCC FAK-/- cells 24 hours post-implantation under dorsal skinfold 
windows. (d) Quantitation of FUCCI cell cycle distribution from 3-dimentional image 
stacks shown in panel c. Sidak’s corrected 2way ANOVA, ***p < 0.001. n = 4 tumors 
per group. (e) Longitudinal imaging of tumour angiogenesis following implantation of 
tumour fragments under dorsal skinfold windows. Red – tagRFP labelled SCC tumor, 
Green – tissue autofluorescence. (f) Quantitation of blood vessel density at day 9. 
Unpaired T-test, *p = 0.0306. Data in all graphs represented as mean +/- s.e.m. n = 3 
tumors per group. 
 
Figure 2 | FAK negatively regulates the expression of IGFBP3 but not other 
IGFBP family members. (a) Relative secreted levels of 53 angiogenesis-related 
proteins measured by antibody capture array from media conditioned by SCC FAK-
wt and FAK-/- cells. Proteins are ordered by fold change. Dotted gray lines indicate 
four-fold enrichment; proteins changed by at least four fold are indicated. Box-and-
whisker plot summarizes the median (line), 25th and 75th percentiles (box) and 5th 
and 95th percentiles (whiskers). (b) Representative anti-IGFBP3 western blot from 
concentrated conditioned media. (c) (q)RT-PCR analysis of IGFBP3 transcript levels 
in SCC FAK-wt and FAK-/- cells. n = 3. (d) Representative PCR analysis of IGFBP 
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family transcript levels in SCC FAK-wt and FAK-/- cells. (e) (q)RT-PCR analysis of 
IGFBP4 transcript levels in SCC FAK-wt and FAK-/- cells. n = 3. (f) (q)RT-PCR 
analysis of IGFBP6 transcript levels in SCC FAK-wt and FAK-/- cells. n = 3. (g) 
Representative anti-IGFBP3 western blot showing secreted IGFBP3 protein levels 
from SCC FAK-wt, SCC FAK-/-, and SCC FAK-kd cells. Data in all graphs 
represented as mean +/- s.e.m. Unpaired T-test, **p < 0.01. 
 
Figure 3 | IGFBP3 regulates cell cycle progression but not tumor angiogenesis. 
(a) Representative anti-IGFBP3 western blot from concentrated media conditioned by 
either SCC FAK-wt, SCC FAK-/-, or SCC FAK-/- IGFBP3 shRNA cells. Anti-FAK 
western blot shows FAK expression status and Anti-tubulin western blot was used a 
loading control. (b) Left - Growth of SCC FAK-wt, SCC FAK-/-, and SCC FAK-/- 
IGFBP3 shRNA tumor xenografts in CD-1 nude mice. Right – Average volume of 
SCC FAK-/- and SCC FAK-/- IGFBP3 shRNA tumors at day 12. Unpaired T-test, 
***p < 0.001. n = 6 tumors per group. (c) Intra-vital imaging of FUCCI expressing 
SCC FAK-wt, SCC FAK-/-, and SCC FAK-/- IGFBP3 shRNA cells 24 hours post-
implantation under dorsal skinfold windows. (d) Quantitation of FUCCI cell cycle 
distribution from 3-dimentional image stacks shown in panel c. Values shown for 
SCC FAK-wt and SCC FAK-/- cells are repeated from Fig. 1d. n = 4 tumors per 
group. (e) Fluorescent staining of frozen tissue sections using anti-CD31 antibody 
(red). Nuclei labelled using DAPI (blue). (f) Quantitation of the % area occupied by 
CD31+ cells. Tukey’s corrected one-way ANOVA, ****p < 0.0001. Data in all graphs 
represented as mean +/- s.e.m. n = 3 tumors per group with an average of 3 fields 
measured per tumor. 
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Figure 4 | Nuclear FAK and RUNX1 regulate IGFBP3 expression. (a) 
Representative anti-FAK western blot of cytoplasmic and nuclear fractions prepared 
from a series of SCC cells expressing FAK nuclear localization signal (NLS) mutants. 
(b) (q)RT-PCR analysis of IGFBP3 expression in SCC cells expressing FAK NLS 
mutants. Tukey’s corrected 1way ANOVA, ****p < 0.0001. Data in all graphs 
represented as mean +/- s.e.m. n = 3. (c) Predicted transcription factor binding sites in 
the promoter of Igfbp3. Transcription factors that interact with nuclear FAK in SCC 
cells are displayed in dark grey. (d) Representative western blot showing Runx1 
depletion using shRNA. (e) (q)RT-PCR analysis of IGFBP3 expression in control and 
Runx1 depleted SCC FAK-wt and SCC FAK-/- cells. Sidak’s corrected 2way 
ANOVA, ****p < 0.0001. ns = not significant. n = 3. 
 
Figure 5 | Nuclear FAK interacts with Runx1. (a) Representative western blot of 
anti-FAK immunoprecipitation probed with anti-Runx1 antibody. (b) Representative 
western blot of anti-Runx1 immunoprecipitation probed with anti-FAK antibody. IgG 
control (Ctrl). (c) Interaction network analysis of physical or predicted direct binders 
of Runx1 that interact with FAK in the nucleus of SCC cells (see Supplementary 
Table 2). Runx1 is shown as a square node. Protein node size is proportional to fold 
enrichment in nuclear FAK immunoprecipitations. Node color indicates significance 
of enrichment in nuclear FAK immunoprecipitations. (d) Pathway enrichment 
analysis of KEGG terms in the nuclear FAK interactome of Runx1 binders (Q < 0.01) 
(see Supplementary Fig. 5). (e) Representative western blot of anti-phospho-tyrosine 
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(pTyr) immunoprecipitation probed with anti-Runx1 antibody. (f) 2D gel 
electrophoresis probed with anti-Runx1 antibody. (g) Representative western blot of 
SCC FAK-wt and FAK-/- nuclear lysates probed with anti-Sin3a antibody. (h) 
Western blot of anti-Sin3a immunoprecipitation from SCC FAK-wt and FAK-/- 
nuclear lysates probed with anti-FAK antibody. IgG control (Ctrl) was done using 
SCC FAK-wt nuclear lysates. (i) Western blot of anti-Runx1 immunoprecipitation 
from SCC FAK-wt, SCC FAK-/-, and SCC FAK-wt Runx1 shRNA nuclear lysates 
probed with anti-Sin3a antibody. IgG control (Ctrl) was done using SCC FAK-wt 
nuclear lysates. 
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